Skip to Main Content

The Role of Neuroactive Steroids in Stress, Drug craving and Drug Use in Alcohol Use Disorders

Conditions

Addictive Behaviors | Alcohol Addiction | Mental Health & Behavioral Research

Phase Pilot

What is the purpose of this trial?

The proposed study will enroll 90 treatment seeking individuals with alcohol use disorder (45 Men; 45 Women), who will be randomized to receive either 300mg pregnenolone (n=30), 500mg pregnenolone (n=30) or placebo (n=30) in a double blind manner, for 8 weeks. Throughout the trial, subjects will visit the Yale Stress Center for twice-weekly appointments to assess alcohol use outcomes in person and also via daily smartphone monitoring. In week 2, participants will be exposed to 3 laboratory sessions of guided imagery conditions (stress, drug cue and neutral); one per day across consecutive days in a counterbalanced and random order.

  • Trial with
    Yale University School of Medicine
  • Start Date
    10/21/2018
  • End Date
    07/30/2021
Trial Image

For more information about this study, contact:

Rachel Hart

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    03/13/2020
  • Study HIC
    #1608018179